Danaher Co. (NYSE:DHR) Shares Acquired by MBB Public Markets I LLC

MBB Public Markets I LLC lifted its position in shares of Danaher Co. (NYSE:DHR) by 2,224.7% in the 2nd quarter, Holdings Channel.com reports. The firm owned 49,887 shares of the conglomerate’s stock after purchasing an additional 47,741 shares during the period. MBB Public Markets I LLC’s holdings in Danaher were worth $12,464,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently modified their holdings of DHR. Benjamin Edwards Inc. boosted its position in shares of Danaher by 1.8% during the 2nd quarter. Benjamin Edwards Inc. now owns 2,153 shares of the conglomerate’s stock worth $538,000 after acquiring an additional 38 shares in the last quarter. Patrick M Sweeney & Associates Inc. lifted its stake in Danaher by 3.4% during the second quarter. Patrick M Sweeney & Associates Inc. now owns 1,230 shares of the conglomerate’s stock worth $307,000 after purchasing an additional 40 shares during the last quarter. Trust Co of Kansas boosted its holdings in Danaher by 4.1% in the second quarter. Trust Co of Kansas now owns 1,022 shares of the conglomerate’s stock valued at $255,000 after purchasing an additional 40 shares in the last quarter. Abacus Planning Group Inc. increased its stake in Danaher by 0.7% in the second quarter. Abacus Planning Group Inc. now owns 5,439 shares of the conglomerate’s stock valued at $1,359,000 after purchasing an additional 40 shares during the last quarter. Finally, Certified Advisory Corp raised its holdings in Danaher by 4.5% during the second quarter. Certified Advisory Corp now owns 926 shares of the conglomerate’s stock worth $231,000 after purchasing an additional 40 shares in the last quarter. Institutional investors and hedge funds own 79.05% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research firms recently commented on DHR. Wells Fargo & Company started coverage on shares of Danaher in a research report on Tuesday, August 27th. They issued an “equal weight” rating and a $280.00 target price on the stock. Evercore ISI dropped their price objective on Danaher from $266.00 to $260.00 and set an “outperform” rating on the stock in a report on Tuesday, July 2nd. Bank of America boosted their target price on Danaher from $270.00 to $275.00 and gave the company a “neutral” rating in a report on Wednesday, July 24th. Jefferies Financial Group began coverage on Danaher in a research note on Monday, June 3rd. They set a “buy” rating and a $295.00 price target on the stock. Finally, Stifel Nicolaus boosted their price objective on Danaher from $235.00 to $250.00 and gave the company a “hold” rating in a research note on Wednesday, July 24th. Seven equities research analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the company. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $278.94.

Insider Activity

In related news, SVP Brian W. Ellis sold 9,600 shares of the business’s stock in a transaction dated Thursday, July 25th. The shares were sold at an average price of $275.16, for a total transaction of $2,641,536.00. Following the sale, the senior vice president now owns 20,230 shares of the company’s stock, valued at $5,566,486.80. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. In related news, CEO Rainer Blair sold 9,007 shares of the business’s stock in a transaction dated Wednesday, July 31st. The shares were sold at an average price of $280.00, for a total value of $2,521,960.00. Following the sale, the chief executive officer now directly owns 97,983 shares in the company, valued at approximately $27,435,240. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, SVP Brian W. Ellis sold 9,600 shares of the firm’s stock in a transaction dated Thursday, July 25th. The shares were sold at an average price of $275.16, for a total transaction of $2,641,536.00. Following the transaction, the senior vice president now owns 20,230 shares of the company’s stock, valued at $5,566,486.80. The disclosure for this sale can be found here. Insiders sold 39,659 shares of company stock worth $11,042,433 in the last 90 days. 11.10% of the stock is currently owned by corporate insiders.

Danaher Trading Up 3.4 %

Shares of Danaher stock opened at $276.93 on Friday. The company has a quick ratio of 1.04, a current ratio of 1.43 and a debt-to-equity ratio of 0.33. The firm has a market cap of $205.12 billion, a price-to-earnings ratio of 46.94, a price-to-earnings-growth ratio of 4.55 and a beta of 0.83. Danaher Co. has a 52-week low of $182.09 and a 52-week high of $281.70. The company’s 50-day simple moving average is $268.95 and its 200-day simple moving average is $257.55.

Danaher (NYSE:DHR) last issued its earnings results on Tuesday, July 23rd. The conglomerate reported $1.72 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.57 by $0.15. Danaher had a return on equity of 11.06% and a net margin of 16.94%. The business had revenue of $5.74 billion during the quarter, compared to the consensus estimate of $5.59 billion. During the same period in the prior year, the business posted $2.05 EPS. The company’s revenue for the quarter was down 2.9% on a year-over-year basis. As a group, equities research analysts anticipate that Danaher Co. will post 7.59 earnings per share for the current year.

Danaher Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, October 25th. Stockholders of record on Friday, September 27th will be paid a dividend of $0.27 per share. The ex-dividend date of this dividend is Friday, September 27th. This represents a $1.08 dividend on an annualized basis and a dividend yield of 0.39%. Danaher’s dividend payout ratio (DPR) is presently 18.31%.

About Danaher

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.